tofersen   Click here for help

GtoPdb Ligand ID: 13536

Synonyms: BIIB-067 | BIIB067 | Qalsody®
Approved drug
tofersen is an approved drug (FDA (2023), EMA (2024))
Compound class: Nucleic acid
Comment: Tofersen (BIIB067) is an antisense oligonucleotide that disrupts translation of superoxide dismutase 1 (SOD1). Tofersen was designed to treat cases of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) that are associated with expression of mutated SOD1. In fact tofersen is mutation agnostic, and disrupts expression of normal and mutated, toxic forms of the SOD1 protein. SOD1-ALS/MND accounts for ~2% of all cases.
Classification Click here for help
Compound class Nucleic acid
Compound subclass Antisense oligonucleotide (ASO)
Target SOD1 mRNA
Approved drug? Yes. China NMPA (2024)  |  EU EMA (2024)  |  US FDA (2023)
International Nonproprietary Names Click here for help
INN number INN
10804 tofersen
Synonyms Click here for help
BIIB-067 | BIIB067 | Qalsody®
Database Links Click here for help
CAS Registry No. 2088232-70-4 (source: WHO INN record)
ChEMBL Ligand CHEMBL3833346
DrugBank Ligand DB14782
GtoPdb PubChem SID 500839946
Search PubMed clinical trials tofersen
Search PubMed titles tofersen
Search PubMed titles/abstracts tofersen